Andrew Murphy - Dec 8, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research
Signature
/s/**Andrew Murphy
Stock symbol
REGN
Transactions as of
Dec 8, 2023
Transactions value $
-$5,618,842
Form type
4
Date filed
12/12/2023, 04:05 PM
Previous filing
Dec 6, 2023
Next filing
Dec 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability -$745K -883 -1.49% $843.79 58.5K Dec 8, 2023 Direct
transaction REGN Common Stock Award $0 +3.2K +5.46% $0.00 61.7K Dec 8, 2023 Direct F1
transaction REGN Common Stock Tax liability -$4.31M -5.11K -8.27% $844.09 56.6K Dec 11, 2023 Direct
transaction REGN Common Stock Tax liability -$565K -669 -1.18% $844.09 56K Dec 11, 2023 Direct
holding REGN Common Stock 4.31K Dec 8, 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +11.5K $0.00 11.5K Dec 8, 2023 Common Stock 11.5K $843.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.